J&J accepts $4B Carlyle offer for diagnostics unit (Update)

March 31, 2014
In this Tuesday, July 30, 2013, file photo, large banners hang in an atrium at the headquarters of Johnson & Johnson in New Brunswick, N.J. Johnson & Johnson has accepted an offer of about $4 billion from the private equity firm The Carlyle Group to buy its Ortho-Clinical Diagnostics business the company said Monday, March 31, 2014, that the deal for the blood-testing unit should close by mid-year. (AP Photo/Mel Evans, File)

Johnson & Johnson has accepted an offer of about $4 billion from the private equity firm The Carlyle Group to buy its Ortho-Clinical Diagnostics business.

J&J said Monday that the deal for the blood-testing unit should close by mid-year.

The health care giant had said in January that Washington, D.C.-based Carlyle Group had offered $4.15 billion for the business, and that it would talk to works councils and trade unions representing its employees before making a decision.

The Ortho-Clinical business serves hospitals, testing laboratories and blood banks. It supplies equipment and chemicals to screen donated blood for HIV, hepatitis C and other serious diseases. It also makes technology for advanced testing of blood to diagnose health conditions and to monitor medication effects.

Ortho Clinical Diagnostics is based in New Jersey and employs more than 4,500 employees. It runs factories in Rochester, New York; Pompano Beach, Florida; and Pencoed, Wales.

J&J CEO Alex Gorsky had said last year the company was looking at strategic options for Ortho-Clinical Diagnostics, which doesn't meet the company's long-held strategy of focusing on businesses that rank first or second in their markets.

Shares of J&J rose 78 cents to $98.22 in afternoon trading Monday. They had climbed more than 6 percent so far this year through Friday's close.

Explore further: Carlyle Group makes $4.15B offer for J&J business

Related Stories

Carlyle Group makes $4.15B offer for J&J business

January 16, 2014

Johnson & Johnson said Thursday that it's been offered $4.15 billion by The Carlyle Group for its Ortho-Clinical Diagnostics business, a year after J&J began reviewing strategic options for the blood-testing unit as part ...

Thermo Fisher to buy Life Technologies for $13.6B (Update)

April 15, 2013

Thermo Fisher Scientific Inc. has offered to pay about $13.6 billion to buy genetic testing equipment maker Life Technologies in a cash deal that will create a giant company serving research and specialty diagnostics.

Novartis sells blood transfusion test unit for $1.7 bn

November 11, 2013

Swiss pharmaceuticals giant Novartis said Monday it would sell its blood transfusion diagnostics unit to the Spanish firm Grifols for $1.68 billion (1.25 billion euros), with analysts saying more divestments could lay in ...

Recommended for you

Study shows blood products unaffected by drone trips

December 7, 2016

In what is believed to be the first proof-of-concept study of its kind, Johns Hopkins researchers have determined that large bags of blood products, such as those transfused into patients every day, can maintain temperature ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.